Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

pembrolizumab 604 Carboplatin 372 Paclitaxel 282 Cisplatin 267 Gemcitabine 252 Pemetrexed 193 Bevacizumab 190 Docetaxel 185 Nivolumab 181 Injections 167 Cyclophosphamide 147 atezolizumab 138 Fluorouracil 133 Capecitabine 133 Oxaliplatin 132 Dexamethasone 127 Fulvestrant 113 durvalumab 112 130-nm albumin-bound paclitaxel 110 fludarabine 101 Cetuximab 100 Leucovorin 97 Rituximab 94 venetoclax 90 Lenalidomide 83 enzalutamide 77 Prednisone 76 Azacitidine 74 Irinotecan 72 Ipilimumab 72

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × dacomitinib × 1 year × Clear all

NCT04721106 2026-02-10

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Pfizer

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡